HempMeds® Brasil supports patients interested in CBD as a treatment option, helps them find a doctor or medical specialist with knowledge of CBD, and assists these patients in the approval process to import RSHO™.
To further ensure patients in Brazil are getting the treatment options they need, HempMeds® Brasil regularly hosts educational seminars for the country’s foremost physicians and medical specialists.
Through a comprehensive outreach program, HempMeds® Brasil has generated a network of doctors throughout the country who are knowledgeable of the benefits of CBD and actively prescribe RSHO™ CBD products to their patients.
The Fischer family challenged the government for their right to provide their daughter with CBD, leading to an expedited court case. After just three days hearing the family’s case, the Brazilian courts ruled it “inhumane” to keep our RSHO™ from Anny. ANVISA, the federal health authority of Brazil, granted the Fischer family the first import authorization for RSHO™.
These events are designed with the intention of giving leading doctors in the country the information they need regarding CBD’s safety and efficacy, how it interacts with the body, significant research on CBD, and best practices for prescribing CBD to patients.
• cannot contain substances that may be potentially toxic at the dosages being used;
In addition to the specific quality control, traceability, prescription and dispensation rules, pharmaceuticals rules on monitoring and inspection actions also apply to Cannabis Products.
As cultivation of Cannabis sativa L is still prohibited in Brazil, local manufacturers must import the active ingredient in the form of a plant derivative, phytopharmaceutical, bulk or industrialised product.
• cannot be of modified release, nanotechnological and pegylated;
Within this context, the applicant (either a manufacturer or an importer) must:
Brazil’s Anvisa, for all intents and purposes functions similarly to the United States’ Food and Drug Administration (FDA). Anvisa’s approval of rules to regulate the emerging medical marijuana market represents a significant shift in a right wing government.
In October of this year, Bill No. 5295 of 2019 was presented to the Brazilian Senate to address the issues of medical cannabis and industrial hemp inside the country.
Inside The $390 Million Battle For OnlyFans’ Insatiable Audience
Sechat reports that the Federal Court of the Federal District of Brasilia authorized, early on Tuesday, that the company Schoenmaker Humako Agri-Floriculture, part of the Terra Viva group, can import and grow industrial hemp seeds with THC concentration below 0.3%. The decision is valid from 15 days onward and comes hours after Anvisa files the proposed resolution for the cultivation of the plant for medicinal purposes and research in Brazil.
Anvisa, the Brazilian sanitary surveillance regulatory body, approved the guidelines that allow the sale of medicinal products derived from cannabis. In these new proposals, the procedures for manufacturing and importing such products and the requirements for prescription, sale, and supervision are approved.
Previously, the only legal medical cannabis product available on the Brazilian market was Sativex, which is registered as Mevatyl in Brazil. Mevatyl’s price tag is R$2000, according to Globo, which is approximately $475.